A Phase II Open, Randomised, Controlled Study to Evaluate the Safety and Immunogenicity of a Paediatric Dose (0.25 mL) and the Standard Dose (0.5 mL) of EpaxalÂ® With Reference to Havrix JuniorÂ® Healthy in Healthy Children and Adolescents (≥12 Months - 16 Years of Age) Using a 0/6 Month Schedule.
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2014
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Acronyms EPA
- Sponsors Crucell
- 22 Apr 2007 New trial record.